Company
Headquarters: Cambridge, MA, United States
Employees: 384
CEO: Mr. Joshua B. Cohen
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $380.8 M |
| EBITDA | $39.9 M |
| Gross Profit TTM | $355.3 M |
| Profit Margin | 12.94% |
| Operating Margin | 1.78% |
| Quarterly Revenue Growth | 395.50% |
Amylyx Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: AMLX